Provided by Tiger Trade Technology Pte. Ltd.

Mainz Biomed B.V.

0.8652
-0.0802-8.48%
Post-market: 0.86520.00000.00%16:10 EST
Volume:759.29K
Turnover:601.36K
Market Cap:7.84M
PE:-0.10
High:0.9900
Open:0.9500
Low:0.6000
Close:0.9454
52wk High:8.16
52wk Low:0.6000
Shares:9.06M
Float Shares:9.01M
Volume Ratio:3.35
T/O Rate:8.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.3903
EPS(LYR):-22.3610
ROE:-465.82%
ROA:-114.35%
PB:3.11
PE(LYR):-0.04

Loading ...

Mainz Biomed NV Files Initial Statement of Beneficial Ownership for CEO and Director Guido Baechler

Reuters
·
Jan 27

Massive Insider Move: Major Investor Makes Colossal Bet on Mainz Biomed

TIPRANKS
·
Jan 17

Mainz Biomed NV Files Initial Beneficial Ownership Statement; Kevin Donahue Listed as 10% Owner

Reuters
·
Jan 17

Mainz Biomed Unveils Pancreatic Cancer mRNA Blood Test Study Results at AACR 2026

Reuters
·
Jan 14

Mainz Biomed Provides Review of 2025 Highlights

GlobeNewswire
·
Jan 05

Mainz Biomed Secures State Funding for Pancreatic Cancer Detection Project

Reuters
·
Jan 05

Mainz Biomed NV Partners with DoctorBox to Offer Home DNA Colorectal Cancer Test

Reuters
·
Dec 02, 2025

Mainz Biomed Signs MOU with OncoVanguard8 to Launch ColoAlert in South America

Reuters
·
Nov 18, 2025

Mainz Biomed NV Showcases Cancer Detection Solutions at MEDICA

Reuters
·
Nov 12, 2025

Mainz Biomed NV to Attend Annual Gastroenterological Working Group of Rhineland-Palatinate Meeting

Reuters
·
Nov 10, 2025

Mainz Biomed NV to Attend Maxim Growth Summit in New York City

Reuters
·
Oct 15, 2025

Mainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study

Reuters
·
Oct 08, 2025

Mainz Biomed NV Enters Equity Distribution Agreement for Up to $10 Million in Ordinary Share Sales, Including $2.3 Million via Shelf Registration Statement

Reuters
·
Oct 04, 2025

Mainz Biomed NV to Showcase Future of Colorectal Cancer Screening at World Endoscopy Organization Committee Meeting

Reuters
·
Sep 30, 2025

Mainz Biomed Reports Financial Results for First Half of 2025

TIPRANKS
·
Sep 27, 2025

Mainz Biomed announces commercial launch of ColoAlert in Switzerland

TIPRANKS
·
Sep 23, 2025

Mainz Biomed NV Announces Launch of ColoAlert® in Switzerland and Advances in eAArly DETECT 2 Study

Reuters
·
Sep 23, 2025

Mainz Biomed NV expected to post a loss of $2.80 a share - Earnings Preview

Reuters
·
Sep 05, 2025

Mainz Biomed Announces Regulatory Approval of ColoAlert for Distribution in the United Kingdom

Reuters
·
Sep 02, 2025

Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland

Reuters
·
Aug 13, 2025